Doctors use a regulatory gap to prescribe unauthorized peptide BPC-157
BPC-157 in Canada: doctors use a compounding loophole to prescribe it orally Health Canada warns it lacks approval, safety data, and clear dosing—see the CBC findings
A CBC News investigation says some doctors in Ontario and British Columbia are prescribing an unauthorized peptide called BPC157 by using a regulatory gap that allows it to be compounded as an oral product with a prescription.
Health Canada says BPC157 has not been authorized for sale and has not been assessed for safety, effectiveness, or quality. The agency also says there is limited scientific evidence to support its use and no established human dosing protocols.
The report found doctors promoting the peptide as a wellness and recovery aid, with claims that it may help with muscle growth, inflammation, tissue repair, and healing. Experts interviewed by CBC said the product has little human research behind it and warned that compounding rules should not be used to bypass drug approval oversight. After CBC contacted the clinics, references to BPC157 were removed from their websites, and Health Canada said it was reviewing whether the activity complied with the law.